Teva realigns reporting segments; Canada moved to International Markets from North America

TEVA PHARMACEUTICAL INDUSTRIES LTD

Canada will be reported as part of International Markets segment, not North America, effective Q1 2024.
Recast 2023 and 2022 segment data shows US segment revenue $7,731M (2023) and segment profit $2,394M.
Canada 2023 revenue $393M, down 12.5% from $449M in 2022, included in International Markets.
No impact on previously reported consolidated financial statements; prior periods restated for comparability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.